This study aims to comparatively analyze the therapeutic efficacy upon multiple medication plans over lopinavir/ritonavir (LPV/r), arbidol (ARB), and methylprednisolone on patients with coronavirus disease 2019 (COVID-19). Totally, 75 COVID-19 patients admitted to The First Affiliated Hospital, Zhejiang University School of Medicine from January 22, 2020 to February 29, 2020 were recruited and grouped based on whether or not LPV/r and ARB were jointly used and whether or not methylprednisolone was used. Indexes including body temperature, time for nucleic acid negative conversion, hospital stays, and laboratory indexes were examined and compared. For all patients, there were no significant differences in the change of body temperature, the time for negative conversion, and hospital stays whether LPV/r and ARB were jointly used or not. While for severe and critically severe patients, methylprednisolone noticeably reduced the time for negative conversion. Meanwhile, the clinical efficacy was superior on patients receiving methylprednisolone within 3 days upon admission, and the duration of hospital stays was much shorter when methylprednisolone was given at a total dose of 0–400 mg than a higher dose of >400 mg if all patients received a similar dose per day. Nonetheless, no significant changes across hepatic, renal, and myocardial function indexes were observed. LPV/r combined with ARB produced no noticeably better effect on COVID-19 patients relative to the single-agent treatment. Additionally, methylprednisolone was efficient in severe and critically severe cases, and superior efficacy could be realized upon its early, appropriate, and short-term application.

中文翻译：

---

甲泼尼龙与洛匹那韦/利托那韦联合阿比朵尔治疗2019冠状病毒病的临床疗效

本研究旨在比较洛匹那韦/利托那韦 (LPV/r)、阿比多尔 (ARB) 和甲基强的松龙对 2019 年冠状病毒病 (COVID-19) 患者的多种用药方案的治疗效果。共招募 2020 年 1 月 22 日至 2020 年 2 月 29 日浙江大学医学院附属第一医院收治的 75 例 COVID-19 患者，根据是否联合使用 LPV/r 和 ARB 以及是否联合使用进行分组使用甲基强的松龙。对体温、核酸转阴时间、住院时间、实验室指标等指标进行检查比较。所有患者无论是否联合使用LPV/r和ARB，体温变化、转阴时间、住院时间均无显着差异。而对于重症和危重症患者，甲泼尼龙显着缩短了转阴时间。同时，入院后 3 天内接受甲基强的松龙治疗的患者临床疗效更优，总剂量 0-400 mg 的甲基强的松龙的住院时间远短于所有患者均给予 >400 mg 的更高剂量。每天接受类似的剂量。尽管如此，没有观察到肝、肾和心肌功能指标的显着变化。相对于单药治疗，LPV/r 联合 ARB 对 COVID-19 患者没有明显更好的效果。此外，甲基强的松龙对重症和危重症的疗效显着，早期、适当、短期应用可显着提高疗效。